Next Article in Journal
Barriers to the Access of Bevacizumab in Patients with Solid Tumors and the Potential Impact of Biosimilars: A Physician Survey
Next Article in Special Issue
In Search of Small Molecule Inhibitors Targeting the Flexible CK2 Subunit Interface
Previous Article in Journal
“The 24th Conference” of the Groupement des Pharmacochimistes de l’Arc Atlantique (GP2A)
Previous Article in Special Issue
Exploring the CK2 Paradox: Restless, Dangerous, Dispensable
Open AccessReview

CK2 in Cancer: Cellular and Biochemical Mechanisms and Potential Therapeutic Target

Department of Medicine, School of Medicine, Boston University, Boston, MA 02118, USA
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Academic Editor: Marc Le Borgne
Pharmaceuticals 2017, 10(1), 18; https://doi.org/10.3390/ph10010018
Received: 2 December 2016 / Revised: 23 January 2017 / Accepted: 23 January 2017 / Published: 28 January 2017
CK2 genes are overexpressed in many human cancers, and most often overexpression is associated with worse prognosis. Site-specific expression in mice leads to cancer development (e.g., breast, lymphoma) indicating the oncogenic nature of CK2. CK2 is involved in many key aspects of cancer including inhibition of apoptosis, modulation of signaling pathways, DNA damage response, and cell cycle regulation. A number of CK2 inhibitors are now available and have been shown to have activity against various cancers in vitro and in pre-clinical models. Some of these inhibitors are now undergoing exploration in clinical trials as well. In this review, we will examine some of the major cancers in which CK2 inhibition has promise based on in vitro and pre-clinical studies, the proposed cellular and signaling mechanisms of anti-cancer activity by CK2 inhibitors, and the current or recent clinical trials using CK2 inhibitors. View Full-Text
Keywords: CK2; cancer; proliferation; apoptosis; migration; invasion; signaling pathways; signaling cascades; preclinical models; clinical trials; therapy CK2; cancer; proliferation; apoptosis; migration; invasion; signaling pathways; signaling cascades; preclinical models; clinical trials; therapy
Show Figures

Figure 1

MDPI and ACS Style

Chua, M.M.; Ortega, C.E.; Sheikh, A.; Lee, M.; Abdul-Rassoul, H.; Hartshorn, K.L.; Dominguez, I. CK2 in Cancer: Cellular and Biochemical Mechanisms and Potential Therapeutic Target. Pharmaceuticals 2017, 10, 18.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop